VPIM
CTKB icon

Vanguard Personalized Indexing Management’s Cytek Biosciences CTKB Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.3K Buy
19,066
+6,821
+56% +$32.2K ﹤0.01% 1977
2025
Q4 		$61.8K Buy
12,245
+687
+6% +$3.19K ﹤0.01% 1863
2025
Q3 		$40.1K Sell
11,558
-837
-7% -$3.14K ﹤0.01% 1925
2025
Q2 		$42.1K Buy
+12,395
New +$41.3K ﹤0.01% 1850

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Personalized Indexing Management's CTKB Position: Q1 2026 in Review

Vanguard Personalized Indexing Management increased its Cytek Biosciences (CTKB) stake by 56% in Q1 2026, buying an estimated $32.2K and bringing the position to 19,066 shares worth $83.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1977.

Vanguard Personalized Indexing Management first reported a position in CTKB in Q2 2025 and has held it in 4 quarters since. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Vanguard Personalized Indexing Management held 19,066 shares of Cytek Biosciences worth $83.3K as of Q1 2026.
  • Vanguard Personalized Indexing Management bought 6,821 Cytek Biosciences shares in Q1 2026, an estimated $32.2K.
  • Cytek Biosciences made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #1977 holding.
  • Vanguard Personalized Indexing Management first reported a position in Cytek Biosciences in Q2 2025 and has held it in 4 quarters since.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.